Maria Trojano

List of Publications by Year
in descending order

409 papers	25,470 citations	9264 74 h-index	10158 140 g-index
427 all docs	427 docs citations	427 times ranked	18705 citing authors

#	Article	IF	Citations
1	Pregnancy in multiple sclerosis women with relapses in the year before conception increases the risk of long-term disability worsening. Multiple Sclerosis Journal, 2022, 28, 472-479.	3.0	13
2	Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout duration. Journal of Neurology, 2022, 269, 1463-1469.	3.6	4
3	SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study. Multiple Sclerosis Journal, 2022, 28, 1034-1040.	3.0	37
4	Job satisfaction among physicians and nurses involved in the management of multiple sclerosis: the role of happiness and meaning at work. Neurological Sciences, 2022, 43, 1903-1910.	1.9	8
5	Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis. Journal of Neurology, 2022, 269, 1670-1677.	3.6	39
6	The effect of air pollution on COVIDâ€19 severity in a sample of patients with multiple sclerosis. European Journal of Neurology, 2022, 29, 535-542.	3.3	8
7	Perivascular and endomysial macrophages expressing VEGF and CXCL12 promote angiogenesis in anti-HMGCR immune-mediated necrotizing myopathy. Rheumatology, 2022, 61, 3448-3460.	1.9	9
8	COVID-19 Severity in Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	6.0	57
9	Real world comparison of teriflunomide and dimethyl fumarate in naÃ¯ve relapsing multiple sclerosis patients: Evidence from the Italian MS register. Multiple Sclerosis and Related Disorders, 2022, 58, 103489.	2.0	2
10	Risk of Getting COVID-19 in People With Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	6.0	31
11	Safety of Fingolimod in Patients with Multiple Sclerosis Switched from Natalizumab: Results from TRANSITIONâ€•A 2-Year, Multicenter, Observational, Cohort Study. Brain Sciences, 2022, 12, 215.	2.3	3
12	Comparing natural history of early and late onset pediatric multiple sclerosis. Annals of Neurology, 2022, , .	5.3	6
13	Alteration of the translational readthrough isoform AQP4ex induces redistribution and downregulation of AQP4 in human glioblastoma. Cellular and Molecular Life Sciences, 2022, 79, 140.	5.4	9
14	The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021. Multiple Sclerosis Journal, 2022, 28, 1424-1456.	3.0	16
15	Neuromyelitis optica spectrum disorders associated with systemic sclerosis: a case report and literature review. Neurological Sciences, 2022, , 1.	1.9	1
16	Secondary Prevention in Radiologically Isolated Syndromes and Prodromal Stages of Multiple Sclerosis. Frontiers in Neurology, 2022, 13, 787160.	2.4	9
17	Natalizumab treatment and pregnancy in multiple sclerosis: A reappraisal of maternal and infant outcomes after 6â€‰years. Multiple Sclerosis Journal, 2022, 28, 2137-2141.	3.0	3
18	Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study. Brain, 2022, 145, 2796-2805.	7.6	38

#	Article	IF	Citations
19	Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom. Pharmacoeconomics, 2022, 40, 323-339.	3.3	3
20	Long-term Cognitive Outcomes and Socioprofessional Attainment in People With Multiple Sclerosis With Childhood Onset. Neurology, 2022, 98, e1626-e1636.	1.1	7
21	Interdisciplinary approach to opportunistic infections: staphylococcal meningitis in a patient with multiple sclerosis on treatment with dimethyl fumarate. Internal and Emergency Medicine, 2022, , 1.	2.0	1
22	Confirmed disability progression as a marker of permanent disability in multiple sclerosis. European Journal of Neurology, 2022, , .	3.3	1
23	Early use of high-efficacy diseaseâ€'modifying therapies makes the difference in people with multiple sclerosis: an expert opinion. Journal of Neurology, 2022, 269, 5382-5394.	3.6	32
24	Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis. BMC Medical Research Methodology, 2022, 22, .	3.1	3
25	023â€... Relapse outcomes with natalizumab Q4W vs switch to Q6W. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A20.3-A21.	1.9	0
26	Interrogating large multiple sclerosis registries and databases: what information can be gained?. Current Opinion in Neurology, 2022, 35, 271-277.	3.6	5
27	Seizure medication and planned pregnancy: balancing the risks and outcomes. Expert Review of Neurotherapeutics, 2022, 22, 527-539.	2.8	2
28	Oral nomegestrol acetate and transdermal 17-beta-estradiol for preventing post-partum relapses in multiple sclerosis: The POPARTMUS study. Multiple Sclerosis Journal, 2021, 27, 1458-1463.	3.0	8
29	Clinical outcomes in patients who discontinue natalizumab therapy after 2 years in the Tysabri^{Â®} Observational Program (TOP). Multiple Sclerosis Journal, 2021, 27, 410-419.	3.0	7
30	The introduction of new medications in pediatric multiple sclerosis: Open issues and challenges. Multiple Sclerosis Journal, 2021, 27, 479-482.	3.0	7
31	Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 755-766.	3.0	11
32	Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score. Multiple Sclerosis Journal, 2021, 27, 695-705.	3.0	7
33	Real-world disability improvement in patients with relapsingâ€"remitting multiple sclerosis treated with natalizumab in the Tysabri Observational Program. Multiple Sclerosis Journal, 2021, 27, 719-728.	3.0	15
34	Detection of disability worsening in relapsingâ€remitting multiple sclerosis patients: a realâ€world roving Expanded Disability Status Scale reference analysis from the Italian Multiple Sclerosis Register. European Journal of Neurology, 2021, 28, 567-578.	3.3	6
35	Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors. Multiple Sclerosis Journal, 2021, 27, 430-438.	3.0	19
36	A case report of lateâ€onset atypical Hemolytic Uremic Syndrome during interferon beta in multiple sclerosis: Open issues in literature review. Brain and Behavior, 2021, 11, e01930.	2.2	8

#	Article	IF	Citations
37	The Contribution of Illness Beliefs, Coping Strategies, and Social Support to Perceived Physical Health and Fatigue in Multiple Sclerosis. Journal of Clinical Psychology in Medical Settings, 2021, 28, 149-160.	1.4	17
38	Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110195.	3.5	48
39	Determinants of therapeutic lag in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 1838-1851.	3.0	3
40	Assessing long-term effectiveness of MS treatment â€" a matter of debate. Nature Reviews Neurology, 2021, 17, 197-198.	10.1	2
41	Diseaseâ€Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis. Annals of Neurology, 2021, 89, 780-789.	5.3	370
42	Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register. Neurotherapeutics, 2021, 18, 905-919.	4.4	9
43	Therapeutic recommendations and seasonal influenza vaccine for multiple sclerosis patients in treatment with ocrelizumab: an expert consensus. Journal of Neurology, 2021, 268, 1540-1543.	3.6	4
44	Longitudinal Evaluation of Serum MOG-IgG and AQP4-IgG Antibodies in NMOSD by a Semiquantitative Ratiometric Method. Frontiers in Neurology, 2021, 12, 633115.	2.4	4
45	Long-term comparative analysis of no evidence of disease activity (NEDA-3) status between multiple sclerosis patients treated with natalizumab and fingolimod for up to 4 years. Neurological Sciences, 2021, 42, 4647-4655.	1.9	6
46	Treatment Switching and Discontinuation Over 20 Years in the Big Multiple Sclerosis Data Network. Frontiers in Neurology, 2021, 12, 647811.	2.4	17
47	Magnetoencephalography and High-Density Electroencephalography Study of Acoustic Event Related Potentials in Early Stage of Multiple Sclerosis: A Pilot Study on Cognitive Impairment and Fatigue. Brain Sciences, 2021, 11, 481.	2.3	10
48	A randomized study of natalizumab dosing regimens for relapsingâ€"remitting multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 2240-2253.	3.0	28
49	Multicenter Interventional Phase IV Study for the Assessment of the Effects on Patient's Satisfaction of Peg IFN Beta-1a (Pre-filled Pen) in Subjects With Relapsingâ€"Remitting Multiple Sclerosis Unsatisfied With Other Injectable Subcutaneous Interferons (PLATINUM Study). Frontiers in Neurology, 2021, 12, 637615.	2.4	1
50	Multiple Sclerosis Progression Discussion Tool Usability and Usefulness in Clinical Practice: Cross-sectional, Web-Based Survey. Journal of Medical Internet Research, 2021, 23, e29558.	4.3	8
51	Early treatment delays long-term disability accrual in RRMS: Results from the BMSD network. Multiple Sclerosis Journal, 2021, 27, 1543-1555.	3.0	33
52	Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus. Journal of Neurology, 2021, 268, 3961-3968.	3.6	47
53	Firstâ€line therapies in lateâ€onset multiple sclerosis: An Italian registry study. European Journal of Neurology, 2021, 28, 4117-4123.	3.3	17
54	DMTs and Covidâ€19 severity in MS: a pooled analysis from Italy and France. Annals of Clinical and Translational Neurology, 2021, 8, 1738-1744.	3.7	86

#	Article	IF	Citations
55	The effectiveness of natalizumab vs fingolimodâ€“A comparison of international registry studies. Multiple Sclerosis and Related Disorders, 2021, 53, 103012.	2.0	8
56	Dengue fever in a multiple sclerosis patient taking Ocrelizumab. Multiple Sclerosis Journal, 2021, 27, 135245852110302.	3.0	3
57	Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression. Computer Methods and Programs in Biomedicine, 2021, 208, 106180.	4.7	21
58	Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts. CNS Drugs, 2021, 35, 1217-1232.	5.9	8
59	Guillain-BarrÃ©Âsyndrome after AstraZeneca COVID-19-vaccination: A causal or casual association?. Clinical Neurology and Neurosurgery, 2021, 208, 106887.	1.4	56
60	No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity scoreâ€“matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP). Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110424.	3.5	9
61	Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years. Neurology, 2021, 96, e783-e797.	1.1	54
62	Mitochondria, Oxidative Stress, cAMP Signalling and Apoptosis: A Crossroads in Lymphocytes of Multiple Sclerosis, a Possible Role of Nutraceutics. Antioxidants, 2021, 10, 21.	5.1	25
63	Comparative effectiveness of early intensive or escalation treatment strategies on long term disability trajectories in relapsing multiple sclerosis patients. Journal of the Neurological Sciences, 2021, 429, 117749.	0.6	0
64	Contribution of post marketing studies to define treatment strategies. Journal of the Neurological Sciences, 2021, 429, 117892.	0.6	0
65	Effectiveness and safety of ocrelizumab in a real-world setting: A single center experience from southern italy. Journal of the Neurological Sciences, 2021, 429, 117790.	0.6	1
66	Serum neurofilament light chain in a cohort of multiple sclerosis, MOG-antibody diseases and neuromyelitis optica spectrum disorders patients. Journal of the Neurological Sciences, 2021, 429, 117791.	0.6	0
67	Guillainâ€BarrÃ© syndrome associated with inappropriate secretion of antidiuretic hormone following SARSâ€CoVâ€2 infection: A caseâ€report. Clinical Case Reports (discontinued), 2021, 9, e04667.	0.5	1
68	Perampanel during pregnancy: Description of four cases. Epilepsy and Behavior Reports, 2021, 16, 100490.	1.0	4
69	Etiological research in pediatric multiple sclerosis: A tool to assess environmental exposures (PEDiatric Italian Genetic and enviRonment ExposurE Questionnaire). Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2021, 7, 205521732110590.	1.0	1
70	Illness perceptions and psychological adjustment among persons with multiple sclerosis: the mediating role of coping strategies and social support. Disability and Rehabilitation, 2020, 42, 3780-3792.	1.8	17
71	Risk of secondary progressive multiple sclerosis: A longitudinal study. Multiple Sclerosis Journal, 2020, 26, 79-90.	3.0	52
72	Italian consensus on treatment of spasticity in multiple sclerosis. European Journal of Neurology, 2020, 27, 445-453.	3.3	20

#	Article	IF	Citations
73	The caring experience in multiple sclerosis: Caregiving tasks, coping strategies and psychological wellâ€being. Health and Social Care in the Community, 2020, 28, 236-246.	1.6	17
74	A Pattern of Cognitive Deficits Stratified for Genetic and Environmental Risk Reliably Classifies Patients With Schizophrenia From Healthy Control Subjects. Biological Psychiatry, 2020, 87, 697-707.	1.3	33
75	Efficacy and Safety of Oral Therapies for Relapsing-Remitting Multiple Sclerosis. CNS Drugs, 2020, 34, 65-92.	5.9	13
76	Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder. Multiple Sclerosis and Related Disorders, 2020, 38, 101868.	2.0	29
77	Leveraging real-world data to investigate multiple sclerosis disease behavior, prognosis, and treatment. Multiple Sclerosis Journal, 2020, 26, 23-37.	3.0	55
78	Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1297-1303.	1.9	27
79	Treatment response score to glatiramer acetate or interferon beta-1a. Neurology, 2020, 96, 10.1212/WNL.0000000000010991.	1.1	6
80	Durvalumab and multiple sclerosis: a causal link or simple unmasking?. European Journal of Clinical Pharmacology, 2020, 76, 1773-1774.	1.9	3
81	Investigating the Effects of COVID-19 Quarantine in Migraine: An Observational Cross-Sectional Study From the Italian National Headache Registry (RICe). Frontiers in Neurology, 2020, 11, 597881.	2.4	45
82	A Pilot Longitudinal Evaluation of MicroRNAs for Monitoring the Cognitive Impairment in Pediatric Multiple Sclerosis. Applied Sciences (Switzerland), 2020, 10, 8274.	2.5	2
83	Association of Sustained Immunotherapy With Disability Outcomes in Patients With Active Secondary Progressive Multiple Sclerosis. JAMA Neurology, 2020, 77, 1398.	9.0	21
84	Delay from treatment start to full effect of immunotherapies for multiple sclerosis. Brain, 2020, 143, 2742-2756.	7.6	24
85	Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis. Brain, 2020, 143, 3013-3024.	7.6	53
86	Effect of Cladribine on Neuronal Apoptosis: New Insight of In Vitro Study in Multiple Sclerosis Therapy. Brain Sciences, 2020, 10, 548.	2.3	6
87	Effects of 2-year treatment with dimethyl fumarate on cognition and functional impairment in patients with relapsing remitting multiple sclerosis. Neurological Sciences, 2020, 41, 3185-3193.	1.9	15
88	Early clinical markers of aggressive multiple sclerosis. Brain, 2020, 143, 1400-1413.	7.6	32
89	Aggressive multiple sclerosis (2): Treatment. Multiple Sclerosis Journal, 2020, 26, 1045-1063.	3.0	21
90	Aggressive multiple sclerosis (1): Towards a definition of the phenotype. Multiple Sclerosis Journal, 2020, 26, 1031-1044.	3.0	39

#	Article	IF	Citations
91	Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurology, The, 2020, 19, 307-316.	10.2	219
92	Long-term effectiveness in patients previously treated with cladribine tablets: a real-world analysis of the Italian multiple sclerosis registry (CLARINET-MS). Therapeutic Advances in Neurological Disorders, 2020, 13, 175628642092268.	3.5	30
93	Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide. Journal of the Neurological Sciences, 2020, 416, 117011.	0.6	36
94	Tissue Distribution of the Readthrough Isoform of AQP4 Reveals a Dual Role of AQP4ex Limited to CNS. International Journal of Molecular Sciences, 2020, 21, 1531.	4.1	18
95	Italian validation of the caregiving tasks in multiple sclerosis scale (CTiMSS). Neurological Sciences, 2020, 41, 1881-1889.	1.9	0
96	Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP). Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 660-668.	1.9	97
97	PBMC of Multiple Sclerosis Patients Show Deregulation of OPA1 Processing Associated with Increased ROS and PHB2 Protein Levels. Biomedicines, 2020, 8, 85.	3.2	17
98	Effectiveness of fingolimod in real-world relapsing-remitting multiple sclerosis Italian patients: the GENIUS study. Neurological Sciences, 2020, 41, 2843-2851.	1.9	7
99	A method to compare prospective and historical cohorts to evaluate drug effects. Application to the analysis of early treatment effectiveness of intramuscular interferon-Î²1a in multiple sclerosis patients. Multiple Sclerosis and Related Disorders, 2020, 40, 101952.	2.0	0
100	Italian multiple sclerosis register as the basis for post-authorization safety studies. European Journal of Public Health, 2020, 30, .	0.3	0
101	Lymphocyte Count and Body Mass Index as Biomarkers of Early Treatment Response in a Multiple Sclerosis Dimethyl Fumarate-Treated Cohort. Frontiers in Immunology, 2019, 10, 1343.	4.8	11
102	Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register. Journal of Neurology, 2019, 266, 3098-3107.	3.6	1
103	Association between miRNAs expression and cognitive performances of Pediatric Multiple Sclerosis patients: A pilot study. Brain and Behavior, 2019, 9, e01199.	2.2	26
104	DP71 and SERCA2 alteration in human neurons of a Duchenne muscular dystrophy patient. Stem Cell Research and Therapy, 2019, 10, 29.	5.5	5
105	Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. Lancet Neurology, The, 2019, 18, 185-197.	10.2	110
106	Autophagy markers LC3 and p62 accumulate in immuneâ€mediated necrotizing myopathy. Muscle and Nerve, 2019, 60, 315-327.	2.2	31
107	Defining the role of NG2-expressing cells in experimental models of multiple sclerosis. A biofunctional analysis of the neurovascular unit in wild type and NG2 null mice. PLoS ONE, 2019, 14, e0213508.	2.5	33
108	AQP4ex is crucial for the anchoring of AQP4 at the astrocyte end-feet and for neuromyelitis optica antibody binding. Acta Neuropathologica Communications, 2019, 7, 51.	5.2	48

#	Article	IF	Citations
109	Host-Cell Type Dependent Features of Recombinant Human Aquaporin-4 Orthogonal Arrays of Particlesâ€"New Insights for Structural and Functional Studies. Cells, 2019, 8, 119.	4.1	3
110	Development and validation of the ID-EC - the ITALIAN version of the identify chronic migraine. Journal of Headache and Pain, 2019, 20, 15.	6.0	7
111	The Italian multiple sclerosis register. Neurological Sciences, 2019, 40, 155-165.	1.9	59
112	Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 458-468.	1.9	71
113	Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study. Multiple Sclerosis and Related Disorders, 2019, 28, 235-243.	2.0	35
114	Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. JAMA - Journal of the American Medical Association, 2019, 321, 175.	7.4	336
115	Multiple sclerosis registries in Europe â€“ An updated mapping survey. Multiple Sclerosis and Related Disorders, 2019, 27, 171-178.	2.0	47
116	Antiâ€inflammatory diseaseâ€modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study. European Journal of Neurology, 2019, 26, 363-370.	3.3	12
117	Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS. Multiple Sclerosis Journal, 2019, 25, 591-600.	3.0	13
118	Synthesis Approaches to (â^')-Cytoxazone, a Novel Cytokine Modulator, and Related Structures. , 2019, , 02-35.		0
119	Supramolecular aggregation of aquaporinâ€4 is different in muscle and brain: correlation with tissue susceptibility in neuromyelitis optica. Journal of Cellular and Molecular Medicine, 2018, 22, 1236-1246.	3.6	14
120	Complexity of MS management in the current treatment era. Neurology, 2018, 90, 761-762.	1.1	4
121	Pregnancy decision-making in women with multiple sclerosis treated with natalizumab. Neurology, 2018, 90, e823-e831.	1.1	102
122	Natalizumab reduces serum pro-angiogenic activity in MS patients. Neurological Sciences, 2018, 39, 725-731.	1.9	4
123	Progress in multiple sclerosis â€" from diagnosis to therapy. Nature Reviews Neurology, 2018, 14, 72-74.	10.1	8
124	Pregnancy decision-making in women with multiple sclerosis treated with natalizumab. Neurology, 2018, 90, e832-e839.	1.1	74
125	Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurology, The, 2018, 17, 162-173.	10.2	4,605
126	Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. Lancet Neurology, The, 2018, 17, 405-415.	10.2	238

#	Article	IF	Citations
127	Environmental modifiable risk factors for multiple sclerosis: Report from the 2016 ECTRIMS focused workshop. Multiple Sclerosis Journal, 2018, 24, 590-603.	3.0	101
128	Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis. Multiple Sclerosis Journal, 2018, 24, 642-652.	3.0	37
129	Cerebrospinal fluid neurofilament light levels mark grey matter volume in clinically isolated syndrome suggestive of multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 1039-1045.	3.0	19
130	Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study. Multiple Sclerosis Journal, 2018, 24, 963-973.	3.0	79
131	Combined microRNA and mRNA expression analysis in pediatric multiple sclerosis: an integrated approach to uncover novel pathogenic mechanisms of the disease. Human Molecular Genetics, 2018, 27, 66-79.	2.9	65
132	Cladribine versus fingolimod, natalizumab and interferon Î² for multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 1617-1626.	3.0	36
133	A rare association of anti-alanine-transfer RNA synthetase (anti-PL12) syndrome and sporadic inclusion body myositis. Scandinavian Journal of Rheumatology, 2018, 47, 336-337.	1.1	2
134	085â€…Clinical outcomes were better for relapsing-remitting multiple sclerosis (RRMS) patients who remained on natalizumab compared to those who switched to oral or injectable therapies after 2 years in the tysabri^{Â®} observational program (TOP). Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, A34.2-A34.	1.9	0
135	Investigating the Role of MicroRNA and Transcription Factor Co-regulatory Networks in Multiple Sclerosis Pathogenesis. International Journal of Molecular Sciences, 2018, 19, 3652.	4.1	40
136	PND10 - GENIUS RWE STUDY (FINGOLIMOD REAL WORLD EVIDENCE ITALIAN MULTICENTER OBSERVATIONAL) Tj ETQq0 0 0 rgBT /Over	0.3	1
137	Novel Assessment of Real-world Effectiveness of Ocrelizumab for Treatment of Patients with Relapsing and Primary Progressive Multiple Sclerosis: Design of a Multicenter Non-interventional Study (musicale Study). Multiple Sclerosis and Related Disorders, 2018, 26, 256-257.	2.0	0
138	Silent lesions on MRI imaging â€“ Shifting goal posts for treatment decisions in multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 1569-1577.	3.0	8
139	Gender Inequities in the Multiple Sclerosis Community: A Call for Action. Annals of Neurology, 2018, 84, 958-959.	5.3	10
140	Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting. Multiple Sclerosis and Related Disorders, 2018, 24, 11-19.	2.0	17
141	Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy. Journal of the Neurological Sciences, 2018, 391, 72-76.	0.6	22
142	Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis. JAMA Neurology, 2018, 75, 1407.	9.0	20
143	Contribution of different relapse phenotypes to disability in multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 266-276.	3.0	30
144	Treatment decisions in multiple sclerosis â€” insights from real-world observational studies. Nature Reviews Neurology, 2017, 13, 105-118.	10.1	154

#	Article	IF	Citations
145	Translational readthrough generates new astrocyte AQP4 isoforms that modulate supramolecular clustering, glial endfeet localization, and water transport. Glia, 2017, 65, 790-803.	4.9	70
146	Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 196-203.	1.9	49
147	Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. Lancet Neurology, The, 2017, 16, 271-281.	10.2	134
148	Prognostic indicators in pediatric clinically isolated syndrome. Annals of Neurology, 2017, 81, 729-739.	5.3	34
149	Lymphocyte subsets as biomarkers of therapeutic response in Fingolimod treated Relapsing Multiple Sclerosis patients. Journal of Neuroimmunology, 2017, 303, 75-80.	2.3	18
150	Gender differences in safety issues during Fingolimod therapy: Evidence from a realâ€life Relapsing Multiple Sclerosis cohort. Brain and Behavior, 2017, 7, e00804.	2.2	22
151	Managing the transition (ManTra): a resource for persons with secondary progressive multiple sclerosis and their health professionals: protocol for a mixed-methods study in Italy. BMJ Open, 2017, 7, e017254.	1.9	16
152	Management of pregnancy-related issues in multiple sclerosis patients: the need for an interdisciplinary approach. Neurological Sciences, 2017, 38, 1849-1858.	1.9	30
153	Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS. Neurology, 2017, 89, 1050-1059.	1.1	38
154	Age and disability drive cognitive impairment in multiple sclerosis across disease subtypes. Multiple Sclerosis Journal, 2017, 23, 1258-1267.	3.0	209
155	Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practice. Multiple Sclerosis Journal, 2017, 23, 1346-1357.	3.0	18
156	Cell-based therapeutic strategies for multiple sclerosis. Brain, 2017, 140, 2776-2796.	7.6	139
157	Towards personalized therapy for multiple sclerosis: prediction of individual treatment response. Brain, 2017, 140, 2426-2443.	7.6	94
158	Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, jnnp-2014-309690.	1.9	90
159	Environmental Factors and Their Regulation of Immunity in Multiple Sclerosis. , 2016, , 99-111.		1
160	Epoch Analysis of On-Treatment Disability Progression Events over Time in the Tysabri Observational Program (TOP). PLoS ONE, 2016, 11, e0144834.	2.5	8
161	Defining secondary progressive multiple sclerosis. Brain, 2016, 139, 2395-2405.	7.6	281
162	Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis. European Journal of Neurology, 2016, 23, 729-736.	3.3	21

#	Article	IF	Citations
163	Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1343-1349.	1.9	63
164	Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 944-951.	1.9	88
165	THC:CBD Observational Study Data: Evolution of Resistant MS Spasticity and Associated Symptoms. European Neurology, 2016, 75, 4-8.	1.4	2
166	Comparative efficacy of first-line natalizumab vs IFN-Î² or glatiramer acetate in relapsing MS. Neurology: Clinical Practice, 2016, 6, 102-115.	1.6	33
167	Tetrahydrocannabinol:Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily Practice. European Neurology, 2016, 76, 216-226.	1.4	40
168	The clinical perspective: How to personalise treatment in MS and how may biomarkers including imaging contribute to this?. Multiple Sclerosis Journal, 2016, 22, 18-33.	3.0	20
169	History of multiple sclerosis in 2 successive pregnancies. Neurology, 2016, 87, 1360-1367.	1.1	16
170	Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1133-1137.	1.9	76
171	The heritage of glatiramer acetate and its use in multiple sclerosis. Multiple Sclerosis and Demyelinating Disorders, 2016, 1, .	1.1	14
172	Long-Term Data of Efficacy, Safety, and Tolerability in a Real-Life Setting of THC/CBD Oromucosal Spray-Treated Multiple Sclerosis Patients. Journal of Clinical Pharmacology, 2016, 56, 845-851.	2.0	19
173	Predictors of longâ€term disability accrual in relapseâ€onset multiple sclerosis. Annals of Neurology, 2016, 80, 89-100.	5.3	158
174	The role of neutralizing antibodies to interferon-Î² as a biomarker of persistent MRI activity in multiple sclerosis: a 7-year observational study. European Journal of Clinical Pharmacology, 2016, 72, 1025-1029.	1.9	7
175	Natalizumab discontinuation is associated with a rebound of cognitive impairment in multiple sclerosis patients. Journal of Neurology, 2016, 263, 1620-1625.	3.6	21
176	Assessing response to interferon-Î² in a multicenter dataset of patients with MS. Neurology, 2016, 87, 134-140.	1.1	98
177	No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon Î²1b therapy in relapsingâ€“remitting multiple sclerosis (the ARIANNA study). Multiple Sclerosis Journal, 2016, 22, 1163-1173.	3.0	24
178	The challenge of comorbidity in clinical trials for multiple sclerosis. Neurology, 2016, 86, 1437-1445.	1.1	48
179	Recommendations for observational studies of comorbidity in multiple sclerosis. Neurology, 2016, 86, 1446-1453.	1.1	64
180	The cognitive reserve theory in the setting of pediatric-onset multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 1741-1749.	3.0	32

#	Article	IF	Citations
181	Exploratory analysis of predictors of patient adherence to subcutaneous interferon beta-1a in multiple sclerosis: TRACER study. Expert Opinion on Drug Delivery, 2016, 13, 799-805.	5.0	13
182	Illness Perception and Well-Being Among Persons with Multiple Sclerosis and Their Caregivers. Journal of Clinical Psychology in Medical Settings, 2016, 23, 33-52.	1.4	39
183	Immunomodulatory therapies delay disease progression in multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 1732-1740.	3.0	48
184	The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 520-532.	3.0	34
185	First evidence of in vivo pro-angiogenic activity of cerebrospinal fluid samples from multiple sclerosis patients. Clinical and Experimental Medicine, 2016, 16, 103-107.	3.6	6
186	The Use of Immunosuppressant Therapy for Multiple Sclerosis in Italy: A Multicenter Retroprospective Study. PLoS ONE, 2016, 11, e0157721.	2.5	5
187	The Cost of Relapsing-Remitting Multiple Sclerosis Patients Who Develop Neutralizing Antibodies during Interferon Beta Therapy. PLoS ONE, 2016, 11, e0159214.	2.5	4
188	Comparative efficacy of switching to natalizumab in active multiple sclerosis. Annals of Clinical and Translational Neurology, 2015, 2, 373-387.	3.7	57
189	Effectiveness and Tolerability of THC/CBD Oromucosal Spray for Multiple Sclerosis Spasticity in Italy: First Data from a Large Observational Study. European Neurology, 2015, 74, 178-185.	1.4	20
190	A comparison of the brief international cognitive assessment for multiple sclerosis and the brief repeatable battery in multiple sclerosis patients. BMC Neurology, 2015, 15, 204.	1.8	31
191	Multiple sclerosis in Latin America: A different disease course severity? A collaborative study from the MSBase Registry. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2015, 1, 205521731560019.	1.0	5
192	Development of an Aquaporin-4 Orthogonal Array of Particle-Based ELISA for Neuromyelitis Optica Autoantibodies Detection. PLoS ONE, 2015, 10, e0143679.	2.5	7
193	A rare case of multiple sclerosis and McArdle disease. Neurological Sciences, 2015, 36, 1721-1723.	1.9	0
194	Advances in the management of MS symptoms: real-life evidence. Neurodegenerative Disease Management, 2015, 5, 19-21.	2.2	1
195	The Cost of Patients With Relapsing-Remitting Multiple Sclerosis Who Develop Neutralizing Antibodies While Treated With Interferon Beta. Value in Health, 2015, 18, A754.	0.3	1
196	Switch to natalizumab versus fingolimod in active relapsingâ€“remitting multiple sclerosis. Annals of Neurology, 2015, 77, 425-435.	5.3	143
197	Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. Multiple Sclerosis Journal, 2015, 21, 1013-1024.	3.0	249
198	A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: Overview. Multiple Sclerosis Journal, 2015, 21, 263-281.	3.0	273

#	Article	IF	Citations
199	The incidence and prevalence of psychiatric disorders in multiple sclerosis: A systematic review. Multiple Sclerosis Journal, 2015, 21, 305-317.	3.0	381
200	Cerebrospinal fluid neurofilament tracks fMRI correlates of attention at the first attack of multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 396-401.	3.0	20
201	Predictors of disability worsening in clinically isolated syndrome. Annals of Clinical and Translational Neurology, 2015, 2, 479-491.	3.7	43
202	Longâ€term cardiac safety and tolerability of fingolimod in multiple sclerosis: A postmarketing study. Journal of Clinical Pharmacology, 2015, 55, 1131-1136.	2.0	23
203	<scp>BREMSO</scp>: a simple score to predict early the natural course of multiple sclerosis. European Journal of Neurology, 2015, 22, 981-989.	3.3	32
204	The incidence and prevalence of comorbid gastrointestinal, musculoskeletal, ocular, pulmonary, and renal disorders in multiple sclerosis: A systematic review. Multiple Sclerosis Journal, 2015, 21, 332-341.	3.0	39
205	Natalizumab discontinuation and disease restart in pregnancy: a case series. Acta Neurologica Scandinavica, 2015, 131, 336-340.	2.1	43
206	Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis. JAMA Neurology, 2015, 72, 405.	9.0	100
207	Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis. Brain, 2015, 138, 3275-3286.	7.6	76
208	Defining reliable disability outcomes in multiple sclerosis. Brain, 2015, 138, 3287-3298.	7.6	162
209	A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 282-293.	3.0	131
210	A systematic review of the incidence and prevalence of cancer in multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 294-304.	3.0	79
211	A systematic review of the incidence and prevalence of sleep disorders and seizure disorders in multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 342-349.	3.0	100
212	A systematic review of the incidence and prevalence of cardiac, cerebrovascular, and peripheral vascular disease in multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 318-331.	3.0	131
213	Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsingâ€“remitting multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 1159-1171.	3.0	36
214	MS and related disorders: looking for markers of phenotypes. Lancet Neurology, The, 2015, 14, 11-13.	10.2	3
215	Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS. PLoS ONE, 2015, 10, e0122686.	2.5	122
216	Proteomic Profiling in Multiple Sclerosis Clinical Courses Reveals Potential Biomarkers of Neurodegeneration. PLoS ONE, 2014, 9, e103984.	2.5	30

#	Article	IF	Citations
217	Age-related Vascular Differences among Patients Suffering from Multiple Sclerosis. Current Neurovascular Research, 2014, 11, 23-30.	1.1	10
218	Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 1190-1197.	1.9	156
219	Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 845-850.	1.9	66
220	The brief international cognitive assessment for multiple sclerosis (BICAMS): normative values with gender, age and education corrections in the Italian population. BMC Neurology, 2014, 14, 171.	1.8	99
221	The use of multiple population-based data sources for estimating MS sex ratio trends over time. Multiple Sclerosis Journal, 2014, 20, 1551-1552.	3.0	1
222	Computer-assisted rehabilitation of attention in patients with multiple sclerosis: results of a randomized, double-blind trial. Multiple Sclerosis Journal, 2014, 20, 91-98.	3.0	103
223	Risk of relapse phenotype recurrence in multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 1511-1522.	3.0	73
224	Implementation of the â€˜Sapere Miglioraâ€™ information aid for newly diagnosed people with multiple sclerosis in routine clinical practice: a late-phase controlled trial. Multiple Sclerosis Journal, 2014, 20, 1234-1243.	3.0	14
225	Treatment of Relapsing-Remitting Multiple Sclerosis After 24 Doses of Natalizumab. JAMA Neurology, 2014, 71, 954.	9.0	50
226	The MoSt Projectâ€“â€“More Steps in multiple sclerosis: a Delphi method consensus initiative for the evaluation of mobility management of MS patients in Italy. Journal of Neurology, 2014, 261, 526-532.	3.6	5
227	Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group. Neurological Sciences, 2014, 35, 307-316.	1.9	30
228	Pregnancy, sex and hormonal factors in multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 527-536.	3.0	69
229	Predictors and dynamics of postpartum relapses in women with multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 739-746.	3.0	148
230	Fingolimod after natalizumab and the risk of short-term relapse. Neurology, 2014, 82, 1204-1211.	1.1	138
231	Neuropsychological features in childhood and juvenile multiple sclerosis. Neurology, 2014, 83, 1432-1438.	1.1	227
232	Seasonal variation of relapse rate in multiple sclerosis is latitude dependent. Annals of Neurology, 2014, 76, 880-890.	5.3	67
233	Angiogenesis in multiple sclerosis and experimental autoimmune encephalomyelitis. Acta Neuropathologica Communications, 2014, 2, 84.	5.2	85
234	Anxiety state affects information processing speed in patients with multiple sclerosis. Neurological Sciences, 2014, 35, 559-563.	1.9	51

#	Article	IF	Citations
235	The coexistence of well- and ill-being in persons with multiple sclerosis, their caregivers and health professionals. Journal of the Neurological Sciences, 2014, 337, 67-73.	0.6	37
236	Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study. BMC Neurology, 2014, 14, 114.	1.8	27
237	Multiple sclerosis registries in Europe â€“ results of a systematic survey. Multiple Sclerosis Journal, 2014, 20, 1523-1532.	3.0	58
238	The improvement of cognitive functions is associated with a decrease of plasma Osteopontin levels in Natalizumab treated relapsing multiple sclerosis. Brain, Behavior, and Immunity, 2014, 35, 176-181.	4.1	36
239	Emotional and neutral verbal memory impairment in Multiple Sclerosis. Journal of the Neurological Sciences, 2014, 341, 28-31.	0.6	11
240	Guidelines from The Italian Neurological and Neuroradiological Societies for the use of magnetic resonance imaging in daily life clinical practice of multiple sclerosis patients. Neurological Sciences, 2013, 34, 2085-2093.	1.9	46
241	Overexpression of autophagic proteins in the skeletal muscle of sporadic inclusion body myositis. Neuropathology and Applied Neurobiology, 2013, 39, 736-749.	3.2	31
242	Multiple sclerosis spasticity symptoms management. Endocannabinoid system modulator data beyond clinical trials. Expert Review of Neurotherapeutics, 2013, 13, 1-1.	2.8	0
243	Sex as a determinant of relapse incidence and progressive course of multiple sclerosis. Brain, 2013, 136, 3609-3617.	7.6	140
244	The impact of neutralizing antibodies on the risk of disease worsening in interferon Î²â€“treated relapsing multiple sclerosis: a 5Âyear post-marketing study. Journal of Neurology, 2013, 260, 1562-1568.	3.6	43
245	Fluctuations of MS births and UV-light exposure. Acta Neurologica Scandinavica, 2013, 127, 301-308.	2.1	10
246	Verbal fluency deficits in clinically isolated syndrome suggestive of multiple sclerosis. Journal of the Neurological Sciences, 2013, 330, 56-60.	0.6	17
247	Persistence on Therapy and Propensity Matched Outcome Comparison of Two Subcutaneous Interferon Beta 1a Dosages for Multiple Sclerosis. PLoS ONE, 2013, 8, e63480.	2.5	26
248	Lack of information about multiple sclerosis in children can impact parents' sense of competency and satisfaction within the couple. Journal of the Neurological Sciences, 2013, 324, 100-105.	0.6	21
249	Brainstem PML lesion mimicking MS plaque in a natalizumab-treated MS patient. Neurology, 2013, 81, 1470-1471.	1.1	9
250	Observational case-control study of the prevalence of chronic cerebrospinal venous insufficiency in multiple sclerosis: results from the CoSMo study. Multiple Sclerosis Journal, 2013, 19, 1508-1517.	3.0	42
251	Load-dependent dysfunction of the putamen during attentional processing in patients with clinically isolated syndrome suggestive of multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 1153-1160.	3.0	19
252	Natalizumab in pediatric multiple sclerosis: results of a cohort of 55 cases. Multiple Sclerosis Journal, 2013, 19, 1106-1112.	3.0	56

#	Article	IF	Citations
253	Subcutaneous Interferon Î²-1a May Protect against Cognitive Impairment in Patients with Relapsingâ€“Remitting Multiple Sclerosis: 5-Year Follow-up of the COGIMUS Study. PLoS ONE, 2013, 8, e74111.	2.5	53
254	Aquaporin-4 Autoantibodies in Neuromyelitis Optica: AQP4 Isoform-Dependent Sensitivity and Specificity. PLoS ONE, 2013, 8, e79185.	2.5	38
255	Fatigue and its relationships with cognitive functioning and depression in paediatric multiple sclerosis. Multiple Sclerosis Journal, 2012, 18, 329-334.	3.0	77
256	Multigate Quality Doppler Profiles and Morphological/Hemodynamic Alterations in Multiple Sclerosis Patients. Current Neurovascular Research, 2012, 9, 120-127.	1.1	32
257	EXPOSURE TO INTERFERON-Î² THERAPY IN EARLY PREGNANCY: A LITERATURE REVIEW OF PREGNANCY OUTCOMES IN WOMEN WITH MULTIPLE SCLEROSIS. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, A17.2-A17.	1.9	2
258	The frequency of CSF oligoclonal banding in multiple sclerosis increases with latitude. Multiple Sclerosis Journal, 2012, 18, 974-982.	3.0	56
259	The Kurtzke EDSS rank stability increases 4â€...years after the onset of multiple sclerosis: results from the MSBase Registry. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 305-310.	1.9	37
260	Elevated plasma homocysteine levels in patients with multiple sclerosis are associated with male gender. Journal of Neurology, 2012, 259, 2105-2110.	3.6	35
261	Longitudinal changes in social functioning in mildly disabled patients with relapsingâ€“remitting multiple sclerosis receiving subcutaneous interferon Î²-1a: results from the COGIMUS (COGnitive) Tj ETQq1 1 0.784314 rgBT/Overlock	1.9	43
262	Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study. BMC Neurology, 2012, 12, 124.	1.8	82
263	Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study. BMC Neurology, 2012, 12, 165.	1.8	78
264	Increasing age at disability milestones among MS patients in the MSBase Registry. Journal of the Neurological Sciences, 2012, 318, 94-99.	0.6	35
265	Dopaminergic Modulation of CD4+CD25high Regulatory T Lymphocytes in Multiple Sclerosis Patients during Interferon-ÃŸ Therapy. NeuroImmunoModulation, 2012, 19, 283-292.	1.8	43
266	Impact of Natalizumab on Cognitive Performances and Fatigue in Relapsing Multiple Sclerosis: A Prospective, Open-Label, Two Years Observational Study. PLoS ONE, 2012, 7, e35843.	2.5	82
267	Low Serum Urate Levels Are Associated to Female Gender in Multiple Sclerosis Patients. PLoS ONE, 2012, 7, e40608.	2.5	21
268	Serum levels of N-acetyl-aspartate in migraine and tension-type headache. Journal of Headache and Pain, 2012, 13, 389-394.	6.0	23
269	Monocytes P2X7 purinergic receptor is modulated by glatiramer acetate in multiple sclerosis. Journal of Neuroimmunology, 2012, 245, 93-97.	2.3	28
270	Serum levels of N-acetylaspartate in Huntington's disease: Preliminary results. Movement Disorders, 2012, 27, 329-330.	3.9	4

#	Article	IF	Citations
271	Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome. PLoS ONE, 2012, 7, e38661.	2.5	35
272	Geographical Variations in Sex Ratio Trends over Time in Multiple Sclerosis. PLoS ONE, 2012, 7, e48078.	2.5	166
273	Serum and CSF N-acetyl aspartate levels differ in multiple sclerosis and neuromyelitis optica. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 1355-1359.	1.9	29
274	Age-related changes of serum N-acetyl-aspartate in healthy controls. Age and Ageing, 2011, 40, 391-395.	1.6	26
275	Natural History of Multiple Sclerosis: Have Available Therapies Impacted Long-Term Prognosis?. Neurologic Clinics, 2011, 29, 309-321.	1.8	32
276	Anxiety and depression in multiple sclerosis patients around diagnosis. Journal of the Neurological Sciences, 2011, 307, 86-91.	0.6	105
277	Cerebral cortex demyelination and oligodendrocyte precursor response to experimental autoimmune encephalomyelitis. Neurobiology of Disease, 2011, 43, 678-689.	4.4	53
278	Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Groupâ€"Italian Neurological Society. Neurological Sciences, 2011, 32, 351-358.	1.9	17
279	Multiple sclerosis in Italy: cost-of-illness study. Neurological Sciences, 2011, 32, 787-794.	1.9	33
280	Changes in magnetic resonance imaging disease measures over 3 years in mildly disabled patients with relapsing-remitting multiple sclerosis receiving interferon Î²-1a in the COGnitive Impairment in MUltiple Sclerosis (COGIMUS) study. BMC Neurology, 2011, 11, 125.	1.8	11
281	Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. Neurology, 2011, 77, 1887-1895.	1.1	68
282	The evolving diagnostic criteria for multiple sclerosis. Nature Reviews Neurology, 2011, 7, 251-252.	10.1	8
283	Identification of Two Major Conformational Aquaporin-4 Epitopes for Neuromyelitis Optica Autoantibody Binding. Journal of Biological Chemistry, 2011, 286, 9216-9224.	3.4	59
284	Treating multiple sclerosis with natalizumab. Expert Review of Neurotherapeutics, 2011, 11, 1683-1692.	2.8	16
285	Quality of life, depression and fatigue in mildly disabled patients with relapsingâ€"remitting multiple sclerosis receiving subcutaneous interferon beta-1a: 3-year results from the COGIMUS (COGnitive) Tj ETQq1 1 0.784314 rgBT /Overlock	3.0	43
286	Breastfeeding is not related to postpartum relapses in multiple sclerosis. Neurology, 2011, 77, 145-150.	1.1	135
287	Psychosocial issue in children and adolescents with multiple sclerosis. Neurological Sciences, 2010, 31, 467-470.	1.9	42
288	Improving combination trials for multiple sclerosis. Lancet Neurology, The, 2010, 9, 646-647.	10.2	1

#	Article	IF	Citations
289	Neurofilament ELISA validation. Journal of Immunological Methods, 2010, 352, 23-31.	1.4	86
290	Cognitive and psychosocial features in childhood and juvenile MS. Neurology, 2010, 75, 1134-1140.	1.1	198
291	The Multiple Sclerosis Knowledge Questionnaire: a self-administered instrument for recently diagnosed patients. Multiple Sclerosis Journal, 2010, 16, 100-111.	3.0	50
292	An information aid for newly diagnosed multiple sclerosis patients improves disease knowledge and satisfaction with care. Multiple Sclerosis Journal, 2010, 16, 1393-1405.	3.0	64
293	Pregnancy and fetal outcomes after interferon-Î² exposure in multiple sclerosis. Neurology, 2010, 75, 1794-1802.	1.1	142
294	Effects of immunomodulatory treatment with subcutaneous interferon beta-1a oncognitive decline in mildly disabled patients with relapsingâ€"remitting multiple sclerosis. Multiple Sclerosis Journal, 2010, 16, 68-77.	3.0	89
295	The brief neuropsychological battery for children: a screening tool for cognitive impairment in childhood and juvenile multiple sclerosis. Multiple Sclerosis Journal, 2009, 15, 620-626.	3.0	56
296	Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsingâ€"remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study. Multiple Sclerosis Journal, 2009, 15, 779-788.	3.0	172
297	Subcutaneous interferon beta-1a has a positive effect on cognitive performance in mildly disabled patients with relapsingâ€"remitting multiple sclerosis: 2-year results from the COGIMUS study. Therapeutic Advances in Neurological Disorders, 2009, 2, 67-77.	3.5	11
298	COGNITIVE AND PSYCHOSOCIAL FEATURES OF CHILDHOOD AND JUVENILE MS. Neurology, 2009, 72, 1189-1190.	1.1	3
299	Epstein-Barr virus (EBV) and multiple sclerosis association: EBV has a primary or secondary role?. Journal of Neurology, Neurosurgery and Psychiatry, 2009, 80, 469-469.	1.9	4
300	Realâ€life impact of early interferonÎ² therapy in relapsing multiple sclerosis. Annals of Neurology, 2009, 66, 513-520.	5.3	132
301	Aquaporinâ€4 orthogonal arrays of particles are the target for neuromyelitis optica autoantibodies. Glia, 2009, 57, 1363-1373.	4.9	143
302	Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience. Neurological Sciences, 2009, 30, 193-199.	1.9	68
303	Safety profile of Tysabri: international risk management plan. Neurological Sciences, 2009, 30, 159-162.	1.9	31
304	Post-marketing of disease modifying drugs in multiple sclerosis: An exploratory analysis of gender effect in interferon beta treatment. Journal of the Neurological Sciences, 2009, 286, 109-113.	0.6	23
305	Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis. Biologics: Targets and Therapy, 2009, 3, 369-76.	3.2	28
306	observational studies: propensity score analysis of non-randomized data. International MS Journal, 2009, 16, 90-7.	0.3	39

#	Article	IF	Citations
307	Postmarketing evidence of disease-modifying drugs in multiple sclerosis. Neurological Sciences, 2008, 29, 225-226.	1.9	3
308	A Case Report of Double Filtration Plasmapheresis in an Acute Episode of Multiple Sclerosis. Therapeutic Apheresis and Dialysis, 2008, 12, 250-254.	0.9	14
309	Variations of the perforin gene in patients with multiple sclerosis. Genes and Immunity, 2008, 9, 438-444.	4.1	39
310	A sequence variation in the MOG gene is involved in multiple sclerosis susceptibility in Italy. Genes and Immunity, 2008, 9, 7-15.	4.1	20
311	Combination treatment of Glatiramer Acetate and Minocycline affects phenotype expression of blood monocyte-derived dendritic cells in Multiple Sclerosis patients. Journal of Neuroimmunology, 2008, 197, 140-146.	2.3	26
312	Neutralizing and Binding Antibodies to Interferon Beta in Patients with Multiple Sclerosis: A Comparison of Assay Results from Three Italian Centres. Journal of Immunoassay and Immunochemistry, 2008, 30, 40-50.	1.1	6
313	Cognitive and psychosocial features of childhood and juvenile MS. Neurology, 2008, 70, 1891-1897.	1.1	251
314	IS IT TIME TO USE OBSERVATIONAL DATA TO ESTIMATE TREATMENT EFFECTIVENESS IN MULTIPLE SCLEROSIS?. Neurology, 2008, 71, 463-464.	1.1	0
315	Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study. Multiple Sclerosis Journal, 2008, 14, 1225-1233.	3.0	72
316	Multicenter Case-Control Study on Restless Legs Syndrome in Multiple Sclerosis: the REMS Study. Sleep, 2008, 31, 944-952.	1.1	175
317	Multicenter case-control study on restless legs syndrome in multiple sclerosis: the REMS study. Sleep, 2008, 31, 944-52.	1.1	56
318	Is it time to use observational data to estimate treatment effectiveness in multiple sclerosis?. Neurology, 2007, 69, 1478-1479.	1.1	24
319	Caregiver quality of life in multiple sclerosis: a multicentre Italian study. Multiple Sclerosis Journal, 2007, 13, 412-419.	3.0	78
320	Communicating the diagnosis of multiple sclerosis - a qualitative study. Multiple Sclerosis Journal, 2007, 13, 763-769.	3.0	77
321	Immunomodulatory properties of increased levels of liver X receptor Î² in peripheral blood mononuclear cells from multiple sclerosis patients. Experimental Neurology, 2007, 204, 759-766.	4.1	8
322	New natural history of interferon-Î²-treated relapsing multiple sclerosis. Annals of Neurology, 2007, 61, 300-306.	5.3	251
323	Glatiramer Acetate in Multiple Sclerosis: A Review. CNS Neuroscience & Therapeutics, 2007, 13, 178-191.	4.0	48
324	Corrigendum to â€œLinkage disequilibrium screening for multiple sclerosis implicates JAG1 and POU2AF1 as susceptibility genes in Europeansâ€•[J. Neuroimmunol. 179 (2006) 108â€“116]. Journal of Neuroimmunology, 2007, 189, 175-176.	2.3	1

#	Article	IF	Citations
325	Pharmacodynamics of interferon beta in multiple sclerosis patients with or without serum neutralizing antibodies. Journal of Neurology, 2007, 254, 597-604.	3.6	25
326	Treatment of early-onset multiple sclerosis with intramuscular interferonÎ²-1a: long-term results. Neurological Sciences, 2007, 28, 127-132.	1.9	57
327	The Raoâ€™s Brief Repeatable Battery and Stroop test: normative values with age, education and gender corrections in an Italian population. Multiple Sclerosis Journal, 2006, 12, 787-793.	3.0	343
328	Glatiramer acetate induces proâ€“apoptotic mechanisms involving Bclâ€“2, Bax and Cytâ€“c in peripheral lymphocytes from multiple sclerosis patients. Journal of Neurology, 2006, 253, 231-236.	3.6	21
329	Benign multiple sclerosis. Journal of Neurology, 2006, 253, 1054-1059.	3.6	147
330	Italian Multiple Sclerosis Database Network. Neurological Sciences, 2006, 27, s358-s361.	1.9	18
331	Linkage disequilibrium screening for multiple sclerosis implicates JAG1 and POU2AF1 as susceptibility genes in Europeans. Journal of Neuroimmunology, 2006, 179, 108-116.	2.3	29
332	The Italian Multiple Sclerosis Database Network (MSDN): the risk of worsening according to IFNÎ² exposure in multiple sclerosis. Multiple Sclerosis Journal, 2006, 12, 578-585.	3.0	27
333	Early prediction of the long term evolution of multiple sclerosis: the Bayesian Risk Estimate for Multiple Sclerosis (BREMS) score. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 78, 757-759.	1.9	55
334	MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis. Multiple Sclerosis Journal, 2006, 12, 769-774.	3.0	168
335	Cognitive dysfunction in patients with relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal, 2006, 12, 77-87.	3.0	119
336	Osteopontin gene haplotypes correlate with multiple sclerosis development and progression. Journal of Neuroimmunology, 2005, 163, 172-178.	2.3	66
337	The IFNÎ² treatment of multiple sclerosis (MS) in clinical practice: the experience at the MS Center of Bari, Italy. Neurological Sciences, 2005, 26, s179-s182.	1.9	5
338	Subclinical Visual Involvement in Multiple Sclerosis: A Study by MRI, VEPs, Frequency-Doubling Perimetry, Standard Perimetry, and Contrast Sensitivity. , 2005, 46, 1264.		104
339	Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatment. Multiple Sclerosis Journal, 2005, 11, 441-446.	3.0	78
340	Dopamine Fails to Regulate Activation of Peripheral Blood Lymphocytes from Multiple Sclerosis Patients: Effects of IFN-Î². Journal of Interferon and Cytokine Research, 2005, 25, 395-406.	1.2	57
341	Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study. Multiple Sclerosis Journal, 2005, 11, 420-424.	3.0	99
342	Multiple Sclerosis Severity Score. Neurology, 2005, 64, 1144-1151.	1.1	836

#	Article	IF	Citations
343	Age-related gadolinium-enhancement of MRI brain lesions in multiple sclerosis. Journal of the Neurological Sciences, 2005, 239, 95-99.	0.6	54
344	The prevalence of pain in multiple sclerosis. Neurology, 2004, 63, 919-921.	1.1	274
345	Post-receptorial mechanisms underlie functional disregulation of Î²2-adrenergic receptors in lymphocytes from Multiple Sclerosis patients. Journal of Neuroimmunology, 2004, 155, 143-149.	2.3	59
346	Clinical characteristics, course and prognosis of relapsing Devic?s Neuromyelitis Optica. Journal of Neurology, 2004, 251, 47-52.	3.6	246
347	Association between Synapsin III gene promoter polymorphisms and multiple sclerosis. Journal of Neurology, 2004, 251, 165-170.	3.6	20
348	Gender-related effect of clinical and genetic variables on the cognitive impairment in multiple sclerosis. Journal of Neurology, 2004, 251, 1208-1214.	3.6	142
349	European validation of a standardized clinical description of multiple sclerosis. Journal of Neurology, 2004, 251, 1472-1480.	3.6	40
350	Can databasing optimise patient care?. Journal of Neurology, 2004, 251, v79-v82.	3.6	7
351	Atypical forms of multiple sclerosis or different phases of a same disease?. Neurological Sciences, 2004, 25, s323-s325.	1.9	24
352	Italian studies on early-onset multiple sclerosis: the present and the future. Neurological Sciences, 2004, 25, s346-s349.	1.9	20
353	A double blind, placebo-controlled, phase II, add-on study of cyclophosphamide (CTX) for 24 months in patients affected by multiple sclerosis on a background therapy with interferon-beta study denomination: CYCLIN. Journal of the Neurological Sciences, 2004, 223, 69-71.	0.6	27
354	Adrenergic mechanisms in multiple sclerosis: the neuroâ€“immune connection?. Trends in Pharmacological Sciences, 2004, 25, 350-351.	8.7	4
355	Apolipoprotein E genotype does not influence the progression of multiple sclerosis. Journal of Neurology, 2003, 250, 1094-1098.	3.6	40
356	The transition from relapsing-remitting MS to irreversible disability: clinical evaluation. Neurological Sciences, 2003, 24, s268-s270.	1.9	28
357	Refining the linkage analysis on chromosome 10 in 449 sib-pairs with multiple sclerosis. Journal of Neuroimmunology, 2003, 143, 31-38.	2.3	12
358	A whole genome screen for linkage disequilibrium in multiple sclerosis performed in a continental Italian population. Journal of Neuroimmunology, 2003, 143, 97-100.	2.3	17
359	Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypes. Journal of Neuroimmunology, 2003, 136, 46-53.	2.3	154
360	CD45 and multiple sclerosis: the exon 4 C77G polymorphism (additional studies and meta-analysis) and new markers. Journal of Neuroimmunology, 2003, 140, 216-221.	2.3	27

#	Article	IF	Citations
361	Genetic interaction of CTLAâ€4 with HLAâ€DR15 in multiple sclerosis patients. Annals of Neurology, 2003, 54, 119-122.	5.3	46
362	Prolactin and prolactin receptor gene polymorphisms in multiple sclerosis and systemic lupus erythematosus. Human Immunology, 2003, 64, 274-284.	2.4	34
363	Adhesion molecules and matrix metalloproteinases in Multiple Sclerosis: effects induced by Interferon-beta. Brain Research Bulletin, 2003, 61, 357-364.	3.0	30
364	Quality Assurance for Cerebrospinal Fluid Protein Analysis: International Consensus by an Internet-Based Group Discussion. Clinical Chemistry and Laboratory Medicine, 2003, 41, 331-7.	2.3	62
365	Interferon beta in relapsing-remitting multiple sclerosis: an independent postmarketing study in southern Italy. Multiple Sclerosis Journal, 2003, 9, 451-457.	3.0	65
366	Serial immunoprecipitation assays for interferon--(IFN)-beta antibodies in multiple sclerosis patients. European Cytokine Network, 2003, 14, 154-7.	2.0	9
367	Intrathecal synthesis of matrix metalloproteinase-9 in patients with multiple sclerosis: implication for pathogenesis. Multiple Sclerosis Journal, 2002, 8, 222-228.	3.0	96
368	Differential Regulation of Membrane Bound and Soluble ICAM 1 in Human Endothelium and Blood Mononuclear Cells: Effects of Interferon Beta-1a. Cell Communication and Adhesion, 2002, 9, 259-272.	1.0	20
369	Interferon beta-1a counteracts effects of activation on the expression of G-protein-coupled receptor kinases 2 and 3, Î²-arrestin-1, and regulators of G-protein signalling 2 and 16 in human mononuclear leukocytes. Cellular Signalling, 2002, 14, 673-678.	3.6	21
370	Age-related disability in multiple sclerosis. Annals of Neurology, 2002, 51, 475-480.	5.3	163
371	The costs of multiple sclerosis: a cross-sectional, multicenter cost-of-illness study in Italy. Journal of Neurology, 2002, 249, 152-163.	3.6	81
372	LFA-1 expression on CD4+CD45RO+ peripheral blood T-lymphocytes in RR MS: effects induced by rIFNÎ²-1a. Journal of the Neurological Sciences, 2001, 186, 65-73.	0.6	5
373	The differential diagnosis of multiple sclerosis: classification and clinical features of relapsing and progressive neurological syndromes. Neurological Sciences, 2001, 22, S98-S102.	1.9	62
374	A genome screen for multiple sclerosis in Italian families. Genes and Immunity, 2001, 2, 205-210.	4.1	70
375	IFN-Î²1a Modulates the Expression of CTLA-4 and CD28 Splice Variants in Human Mononuclear Cells: Induction of Soluble Isoforms. Journal of Interferon and Cytokine Research, 2001, 21, 809-812.	1.2	21
376	Inhibition of protein kinase C counteracts TNFÎ±-induced intercellular adhesion molecule 1 expression and fluid phase endocytosis on brain microvascular endothelial cells. Brain Research, 2000, 863, 245-248.	2.2	19
377	Interferon Î²-1a downregulates TNFÎ±-induced intercellular adhesion molecule 1 expression on brain microvascular endothelial cells through a tyrosine kinase-dependent pathway. Brain Research, 2000, 881, 227-230.	2.2	20
378	Age at onset in multiple sclerosis. Neurological Sciences, 2000, 21, S825-S829.	1.9	65

#	Article	IF	Citations
379	Linkage analysis of multiple sclerosis with candidate region markers in Sardinian and Continental Italian families. European Journal of Human Genetics, 1999, 7, 377-385.	2.8	38
380	Comparison of clinical and demographic features between affected pairs of Italian Multiple Sclerosis multiplex families; relation to tumour necrosis factor genomic polymorphisms. Journal of the Neurological Sciences, 1999, 162, 194-200.	0.6	13
381	Changes of serum sICAM-1 and MMP-9 induced by rIFNÎ²-1b treatment in relapsing-remitting MS. Neurology, 1999, 53, 1402-1402.	1.1	125
382	ICAM 1 expression and fluid phase endocytosis of cultured brain microvascular endothelial cells following exposure to interferon Î²-1a and TNFÎ±. Journal of Neuroimmunology, 1998, 88, 13-20.	2.3	36
383	Soluble Intercellular Adhesion Molecule-1 (sICAM-1) in serum and cerebrospinal fluid of demyelinating diseases of the central and peripheral nervous system. Multiple Sclerosis Journal, 1998, 4, 39-44.	3.0	19
384	Serum soluble intercellular adhesion molecule-1 in MS: relation to clinical and Gd-MRI activity and to rIFNÎ²-1b treatment. Multiple Sclerosis Journal, 1998, 4, 183-187.	3.0	12
385	Soluble Intercellular Adhesion Molecule-1 (sICAM-1) in serum and cerebrospinal fluid of demyelinating diseases of the central and peripheral nervous system. Multiple Sclerosis Journal, 1998, 4, 39-44.	3.0	9
386	Serum soluble intercellular adhesion molecule-1 in MS: relation to clinical and Gd-MRI activity and to rIFNÎ²-1b treatment. Multiple Sclerosis Journal, 1998, 4, 183-187.	3.0	2
387	Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. Journal of Neurology, 1997, 244, 153-159.	3.6	257
388	Serum IgG to brain microvascular endothelial cells in multiple sclerosis. Journal of the Neurological Sciences, 1996, 143, 107-113.	0.6	16
389	High resolution proton MR spectroscopy of cerebrospinal fluid in MS patients. Comparison with biochemical changes in demyelinating plaques. Journal of the Neurological Sciences, 1996, 144, 182-190.	0.6	73
390	Soluble intercellular adhesion molecule-1 in serum and cerebrospinal fluid of clinically active relapsing-remitting multiple sclerosis. Neurology, 1996, 47, 1535-1541.	1.1	40
391	Magnetic resonance imaging, proton magnetic resonance spectroscopy and cerebrospinal fluid abnormalities in multiple sclerosis. , 1996, , 123-132.		0
392	Multivariate analysis of predictive factors of multiple sclerosis course with a validated method to assess clinical events.. Journal of Neurology, Neurosurgery and Psychiatry, 1995, 58, 300-306.	1.9	113
393	Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report.. Journal of Neurology, Neurosurgery and Psychiatry, 1994, 57, 897-902.	1.9	589
394	A Controlled Trial of Mitoxantrone in Multiple Sclerosis: Serial MRI Evaluation at One Year. Canadian Journal of Neurological Sciences, 1994, 21, 266-270.	0.5	50
395	Disease Duration, Relapse rate and Clinical Course in Multiple Sclerosis: Relation to IgG Production within the Blood Brain Barrier. , 1990, , 23-31.		0
396	Intrathecal IgG Synthesis in Multiple Sclerosis: Correlation with Clinical Parameters. , 1988, , 21-31.		0

#	Article	IF	Citations
397	Blood-cerebrospinal fluid barrier permeability to serum IgG subfractions and measurement of intrathecal IgG synthesis. Journal of the Neurological Sciences, 1986, 73, 325-338.	0.6	1
398	Acute changes in blood-CSF barrier permselectivity to serum proteins after intrathecal methotrexate and CNS irradiation. Journal of Neurology, 1985, 231, 336-339.	3.6	50
399	Heterogeneous models for blood-cerebrospinal fluid barrier permeability to serum proteins in normal and abnormal cerebrospinal fluid/serum protein concentration gradients. Journal of the Neurological Sciences, 1984, 64, 245-258.	0.6	24
400	Blood-CSF barrier permselectivity and measurement of intrathecal IgG synthesis in multiple sclerosis. , 1984, , 441-447.		0
401	Intrathecal IgG synthesis in multiple sclerosis: Comparison between isoelectric focusing and quantitative estimation of cerebrospinal fluid IgG. Journal of Neurology, 1981, 224, 159-169.	3.6	42
402	Isoelectric focusing and quantitative estimation of cerebrospinal fluid and serum IgG in idiopathic polyneuropathy. Journal of Neurology, 1980, 223, 1-12.	3.6	10
403	Isoelectric focusing and crossed immunoelectrofocusing of cerebrospinal fluid proteins in neurological disorders. Acta Neurologica, 1978, 33, 501-17.	0.1	7
404	Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis. Biologics: Targets and Therapy, 0, , 369.	3.2	3
405	Cognitive dysfunction in pediatric-onset multiple sclerosis. , 0, , 134-143.		2
406	The challenge of demonstrating long-term benefit of disease-modifying therapies in multiple sclerosis. , 0, , 244-252.		2
407	Disease Modifying Therapies and COVID-19 Severity in Multiple Sclerosis. SSRN Electronic Journal, 0, , .	0.4	31
408	Do patientsâ€™ and referral centersâ€™ characteristics influence multiple sclerosis phenotypes? Results from the Italian multiple sclerosis and related disorders register. Neurological Sciences, 0, , .	1.9	1
409	Macular ganglion cell-inner plexiform layer defect patterns in multiple sclerosis patients without optic neuritis: A Spectral-Domain-Optical Coherence Tomography Cross-Sectional, Case-Control, Pilot Study. European Journal of Ophthalmology, 0, , 112067212211128.	1.3	0